Celiac disease

Current Opinion in Gastroenterology

Volumn 24, Issue 6, 2008, Pages 687-691

  Catassi, Carlo ^a,b   Fasano, Alessio ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Celiac disease; Genetics; Gluten; Innate and adaptive immunity; Intestinal permeability

Indexed keywords

AT 1001; GLIADIN; GLUTEN; HLA ANTIGEN CLASS 2; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; LARAZOTIDE ACETATE; PLACEBO; PROLYL ENDOPEPTIDASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; CAUCASIAN; CELIAC DISEASE; CLINICAL TRIAL; DOSE RESPONSE; ENZYME THERAPY; ETHNICITY; GASTROINTESTINAL SYMPTOM; GENE FUNCTION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GLUTEN FREE DIET; HLA SYSTEM; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PATHOGENESIS; PREVALENCE; REVIEW; TRANSGENIC CROP;

AUTOIMMUNITY; BIOPSY; CELIAC DISEASE; DIAGNOSIS, DIFFERENTIAL; DIET, GLUTEN-FREE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOLOGIC FACTORS; INTESTINE, SMALL; PREVALENCE; PROGNOSIS; RISK FACTORS; WORLD HEALTH;

EID: 55749114416     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32830edc1e     Document Type: Review

References (25)

1. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001; 120:636-651.
2. Presutti RG, Cangemi JR, Cassidy HD. Celiac disease. Am Fam Phys 2007; 76:1795-1802.
3. Catassi C, Gobetlis G. Coeliac disease epidemiology is alive and kicking, especially in the developing world. Dig Liver Dis 2007; 39:908-910.
4. Sood A, Midha V, Sood N, et al. Prevalence of celiac disease among school children in Punjab, North India. J Gastroenterol Hepatol 2006; 21:1622-1625.
5. Yachha SK, Poddar U. Celiac disease in India. Indian J Gastroenterol 2007; 26:230-237.
6. Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. Am J Gastroenterol 2008; 103:190-195. This is an excellent review focused on the most novel information on the genetics of celiac disease, with particular emphasis on the extra HLA genes recently identified and their potential role in celiac disease pathogenesis.
7. Monsuur AJ, de Bakker PI, Alizadeh BZ, et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet 2005; 37:1341-1344.
8. van Bodegraven AA, Curley CR, Hunt KA, et al. Genetic variation in myosin IXB is associated with ulcerative colitis. Gastroenterology 2006; 131:1768-1774.
9. Sanchez E, Alizadeh BZ, Valdigem G, et al. MYO9B gene polymorphisms are associated with autoimmune diseases in Spanish population. Hum Immunol 2007; 68:610-615.
10. Wapenaar MC, Monsuur AJ, van Bodegraven AA, et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut 2008; 57:463-467. This article reports for the first time the possible involvement of tight junction genes in the pathogenesis of intestinal inflammatory diseases.
11. van Heel DA, Franke L, Hunt KA, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007; 39:827-829.
12. Zhemakova A, Alizadeh BZ, Bevova M, et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 2007; 81:1284-1288.
13. Hunt KA, Zhemakowa A, Turner G, et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008; 40:395-402. This manuscript reports on the identification of several genes related to immune response typical of celiac disease and, most likely, of many other autoimmune diseases.
14. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-678.
15. Catassi C, Fabiani E, Iacono G, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007; 85:160-166.
16. Lanzini A, Lanzarotto F, Mora A, et al. Small intestinal recovery is often incomplete in serum-negative celiacs during gluten free-diet. Gastroenterology 2007; 132:A109.
17. Akobeng AK, Thomas AG. Systematic review: tolerable amount of gluten for people with coeliac disease. Aliment Pharmacol Ther 2008; 27:1044-1052.
18. Gibert A, Espadaler M, Angel Canela M, et al. Consumption of gluten-free products: should the threshold value for trace amounts of gluten be at 20,100 or 200 p.p.m.? Eur J Gastroenterol Hepatol 2006; 18:1187-1195.
19. Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science 2002; 297:2275-2279.
20. Gass J, Bethune MT, Siegel M, et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007; 133:472-480.
21. Mitea C, Havenaar R, Drijfhout JW, et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008; 57:25-32. This paper poses the basis for possible future clinical trials in humans using proteolytic enzymes to completely degraded gluten. This approach may represent a valid alternative to the GFD for the treatment of celiac disease.
22. Benahmed M, Meresse B, Arnulf B, et al. Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease. Gastroenterology 2007; 132:994-1008.
23. Fasano A, Shea-Donohue T. Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2:416-422.
24. Watts T, Berti I, Sapone A, et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci U S A 2005; 102:2916-2921.
25. Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in celiac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007; 26:757-766. This is the first report on clinical trials for the treatment of celiac disease alternative to the GFD.